Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Inclusion Criteria: * Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease * Tumor expression of melanocyte differentiation antigen (MDA: MART-1 = 2+ staining or \> 25%) by immunohistochemistry (IHC) * Expression of human leukocyte antigen (HLA)-A201 * Zubrod performance status of '0-1' at the time of treatment * Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray, computed tomography \[CT\] scan) * Normal cardiac stress test will be required for all patients with any history of cardiac disease Exclusion Criteria: * Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry * Serum creatinine \> 1.6 mg/dL or Creatinine clearance \< 75 ml/min * Serum glutamic oxaloacetic transaminase (SGOT) \> 150 IU or \> 3x upper limit of normal * Bilirubin \> 1.6 mg/dL * Prothrombin time \> 1.5 x control * Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) \< 2.0 L or carbon monoxide diffusing capacity (DLco) (corr for hemoglobin \[Hgb\]) \< 75% will be excluded * Congestive heart failure * Clinically significant hypotension * Symptoms of coronary artery disease * Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy * Ejection fraction \< 50 % (echocardiogram or multi gated acquisition scan \[MUGA\]) * Symptomatic central nervous system metastases greater than 1 cm at time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment * Patients with active infections or oral temperature \> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy * Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy) * Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives * Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy * Current treatment with steroids * Patients must not be receiving any other experimental drugs within 3 weeks of the initiation of the protocol and must have recovered from all side effects of such therapy * Patients for whom we are unable to generate MART-1 specific T cells